Assertio's (ASRT) "Sell (D-)" Rating Reaffirmed at Weiss Ratings

Key Points

• Assertio's stock is reaffirmed with a "sell (D-)" rating by Weiss Ratings, amid mixed assessments from other analysts.
• Shares of Assertio traded at $0.89, with a 52-week range between $0.51 and $1.16, amid a market cap of $85.46 million.
• Recent quarterly earnings showed a loss of ($0.17) per share, missing estimates, while revenue was reported at $29.22 million.

Assertio (NASDAQ:ASRT - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by research analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

Several other research firms have also weighed in on ASRT. Zacks Research lowered Assertio from a "hold" rating to a "strong sell" rating in a research report on Monday, August 25th. HC Wainwright dropped their price target on Assertio from $3.50 to $3.00 and set a "buy" rating on the stock in a research report on Tuesday, August 12th. Two research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $2.38.

Assertio Stock Up 0.2%

Shares of NASDAQ ASRT traded up $0.00 during mid-day trading on Wednesday, hitting $0.89. 109,573 shares of the stock traded hands, compared to its average volume of 318,705. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.34 and a current ratio of 1.59. Assertio has a 52 week low of $0.51 and a 52 week high of $1.16. The company has a market cap of $85.46 million, a price-to-earnings ratio of -1.97 and a beta of 0.28. The stock has a fifty day moving average price of $0.82 and a 200-day moving average price of $0.71.

Assertio (NASDAQ:ASRT - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.07). Assertio had a negative net margin of 36.97% and a negative return on equity of 38.19%. The firm had revenue of $29.22 million for the quarter, compared to the consensus estimate of $27.86 million. Assertio has set its FY 2025 guidance at EPS. Research analysts anticipate that Assertio will post -0.15 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Nantahala Capital Management LLC increased its position in Assertio by 4.4% during the second quarter. Nantahala Capital Management LLC now owns 8,810,073 shares of the company's stock valued at $5,649,000 after acquiring an additional 370,311 shares during the last quarter. Belpointe Asset Management LLC purchased a new stake in Assertio in the first quarter worth about $65,000. CM Management LLC increased its position in Assertio by 18.8% in the first quarter. CM Management LLC now owns 475,000 shares of the company's stock worth $320,000 after buying an additional 75,000 shares in the last quarter. Finally, TSP Capital Management Group LLC increased its position in Assertio by 12.2% in the second quarter. TSP Capital Management Group LLC now owns 316,875 shares of the company's stock worth $203,000 after buying an additional 34,550 shares in the last quarter. Hedge funds and other institutional investors own 48.96% of the company's stock.

Assertio Company Profile

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.